Co-Authors
This is a "connection" page, showing publications co-authored by NAVAL DAVER and TAREQ ABUASAB.
Connection Strength
0.663
-
BRAF mutation in myeloid neoplasm: incidences and clinical outcomes. Leuk Lymphoma. 2024 Sep; 65(9):1344-1349.
Score: 0.243
-
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications. Am J Hematol. 2024 07; 99(7):1434-1436.
Score: 0.243
-
Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis. JCO Oncol Pract. 2024 Jul 16; OP2400027.
Score: 0.062
-
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol. 2024 Apr; 11(4):e276-e286.
Score: 0.060
-
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol. 2023 03; 98(3):E53-E56.
Score: 0.055